TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05546242
Drug: Antiretroviral
Normalized name: Antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
Study: NCT05385575
Drug: KN056 (0.3mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive assigned single dose of KN056 on Day 1
Study: NCT05385575
Drug: KN056 (1.0mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study: NCT05385575
Drug: KN056 (3.0mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study: NCT06679673
Drug: SHR2554
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554
Study: NCT05385575
Drug: KN056 (6.0mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study: NCT05385575
Drug: KN056 (12.0mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study: NCT05385575
Drug: KN056 (18.0mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study: NCT05981703
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in accordance with relevant local guidelines and/or prescribing information.
Study: NCT06679764
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pataints received opioid analgesia with genaral anesthesia
Study: NCT05553587
Drug: Amara drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational drug is approved with a reduced dossier without indication according to Art. 25 para. 1 KPAV (SR 812.212.24). This study follows the indication text licensed by Swissmedic: ... Weleda Amara-Drops can be used for digestive complaints such as heartburn, flatulence and bloating after meals, to stimulate the bile flow and for loss of appetite and nausea. The effect of Weleda Amara drops is based on a balanced mixture of medicinal plants with tonic (invigorating) and aromatic bitter substances, which are suitable for stimulating digestion. Further, no side effects have been reported in past studies so far. All these reasons lead us to the conclusion that this study is only associated with minimal risks and should be classified in risk category A.
Study: NCT06149091
Drug: Hemagglutinase
Normalized name: Bordetella pertussis filamentous hemagglutinin vaccine, inactivated / Bordetella pertussis pertactin vaccine, inactivated / Bordetella pertussis toxoid vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Infanrix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin injection (Batroxobin) is an enzymatic hemostatic agent refined from the venom of the Brazilian lancehead snake. It promotes clot formation at the bleeding site, characterized by rapid and effective hemostasis and high safety. It is now widely used for clinical prevention and treatment of perioperative bleeding and oozing. Multiple randomized controlled studies have evaluated the safety and efficacy of intravenous/topical application of thrombin in various trauma and surgical settings.
Study: NCT06605131
Drug: GP+CCRT
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles
Study: NCT06602219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00110734
Drug: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05607563
Drug: PM1009 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive PM1009 intravenously, every 2 weeks
Study: NCT05094596
Drug: Standart treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.
Study: NCT05103657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05601778
Drug: HSK31858
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
Study: NCT05601778
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo comparator of study
Study: NCT04736758
Drug: GP681 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
Study: NCT04736758
Drug: GP681 Simulant
Normalized name: STAPHYLOCOCCUS SIMULANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
Study: NCT05528679
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered subcutaneously Q4W
Study: NCT06608940
Drug: BC3402
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous. BC3402 to be administered after completion of the infusion of durvalumab and/or tremelimumab on the days when BC3402 is to be administered with durvalumab and/or tremelimumab
Study: NCT01004315
Drug: KUC-7483
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01004315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05471609
Drug: levodopa/carbidopa oral formulation A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
Study: NCT05471609
Drug: levodopa/carbidopa oral formulation B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
Study: NCT05471609
Drug: levodopa/carbidopa oral formulation C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outer sachet 50mg CD/200mg LD and inner sachet 50mg CD /200mg LD
Study: NCT05739734
Drug: CRIS100
Approvals — FDA: no, EMA: no, PMDA: no
Description: local application of CRIS100
Study: NCT05547906
Drug: ASCA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion Twice a Week, 8 times per each Cycle
Study: NCT05371639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identified to Tian Ma Bian Chun Zhi Gan, 0.1g per pill which contains 0mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
Study: NCT05620563
Drug: LY3857210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05620563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04835441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded placebo matching ALPN-101 will be administered.
Study: NCT04540692
Drug: Cyclophosphamide + Doxorrubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles
Study: NCT05368558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05694130
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
Study: NCT06384482
Drug: SNC115 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNC115 Injection is DLL3 CART.
Study: NCT04830241
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
Study: NCT06299033
Drug: hNPC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: hNPC01, human forebrain neural progenitor cell product, intracerebral injection
Study: NCT06474481
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Study: NCT06474481
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ，1 cycle = 28 days
Study: NCT06458244
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for AML consolidation treatment
Study: NCT05268419
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation of 35%-ethanol spray
Study: NCT05673993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given subcutaneous placebo once a week.
Study: NCT06210945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05814393
Drug: Treatment Period(JW0201)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
Study: NCT05814393
Drug: Treatment Period(Placebo)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
Study: NCT05814393
Drug: Extension Period(JW0201)
Normalized name: EXTENSION TUBES
Approvals — FDA: no, EMA: no, PMDA: no
Description: JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)
Study: NCT06608030
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving the same volume of normal saline during induction of anesthesia.
Study: NCT05287399
Drug: ASC61 200 mg 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg of ASC61 orally once daily for cycles of 28 days
Study: NCT05287399
Drug: ASC61 200 mg 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of ASC61 orally twice daily for cycles of 28 days
Study: NCT05287399
Drug: ASC61 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of ASC61 orally twice daily for cycles of 28 days
Study: NCT05287399
Drug: ASC61 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ASC61 orally twice daily for cycles of 28 days
Study: NCT05287399
Drug: ASC61 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of ASC61 orally twice daily for cycles of 28 days
Study: NCT06204016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered as placebo-controlled condition (P-Tabletten White 7mm, Lichtenstein)
Study: NCT04868565
Drug: Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Normalized name: Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight.
Study: NCT06606886
Drug: Tablet Hydroxyurea (Group B)
Normalized name: hydroxyurea Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
Study: NCT06608433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills will be administered as a single oral dose
Study: NCT04703842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRD-001 matching placebo
Study: NCT02483936
Drug: Olmesartan 40mg + Hydrochlorothiazide 25mg
Normalized name: olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet a day
Study: NCT06285240
Drug: MK-1167
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg and 5 mg oral capsules
Study: NCT06285240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1167 matching placebo administered oral capsules
Study: NCT06533280
Drug: Part A, C and D: VH3739937 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions
Study: NCT06533280
Drug: Part A: VH3739937 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions.
Study: NCT06533280
Drug: Part A and C: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Placebo in moderate fat/moderate calorie conditions
Study: NCT06533280
Drug: Part B: Treatment A
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH3739937, 500 mg(single dose given as 5 x 100 mg tablets). administered under moderate fat/moderate calorie conditions (reference)
Study: NCT06533280
Drug: Part B: Treatment B
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH3739937, 500 mg (single dose given as 500 mg tablet) administered under moderate fat/moderate calorie conditions (test)
Study: NCT06533280
Drug: Part B: Treatment C
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH3739937, 500 mg single tablet administered under fasted conditions.
Study: NCT06533280
Drug: Part B: Treatment D
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH3739937, 500 mg single tablet administered under low-fat/ low calorie conditions.
Study: NCT06533280
Drug: Part B: Treatment E
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH3739937, 500 mg single tablet administered under high-fat/ high calorie conditions.
Study: NCT06533280
Drug: Part D: Probe cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.
Study: NCT06679465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs placebo
Study: NCT05934539
Drug: ALG.APV-527
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells such as CD8+ T cells and natural killer (NK) cells, and the tumor associated antigen 5T4. ALG.APV-527 is being co-developed by Alligator Bioscience AB (Lund, Sweden) and Aptevo Therapeutics Inc. (Seattle, WA, USA) as a cancer immunotherapy.
Study: NCT05118906
Drug: BP1.4979 active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets 15 mg of BP1.4979 per day
Study: NCT05118906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of placebo per day
Study: NCT06106334
Drug: S309309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as oral capsules
Study: NCT04792489
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting chemotherapy
Study: NCT05135624
Drug: SP16 (6mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP16 will be administered as 2 concurrent, separate 2 mL s.c injections of 3mg/mL SP16
Study: NCT05135624
Drug: SP16 (12 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
Study: NCT06312423
Drug: Oligonucleotides, Phosphorothioate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days
Study: NCT04902872
Drug: CBX-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
Study: NCT05904691
Drug: OCU-10-C-110 for Injection
Normalized name: Tru-Blu C-Hex 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCU-10-C-110 for Injection in one of 3 doses
Study: NCT05531682
Drug: HB0017
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive HB0017 in different dosing regimens
Study: NCT05925725
Drug: • harpagozid • boswellin = LOXACON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy
Study: NCT04691700
Drug: Goreisan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
Study: NCT06237101
Drug: High dose of remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
Study: NCT06237101
Drug: Medium dose of remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
Study: NCT05015127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05015127
Drug: HBM9161 680 mg qw by q2w from week 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM9161 680 mg qw by q2w from week 7
Study: NCT05015127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo qw by HBM9161 680mg qw from week 12
Study: NCT05643508
Drug: (P) DWC202206
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of DWC202206 A mg
Study: NCT05643508
Drug: (P) DWC202207
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of DWC202207 B/C mg
Study: NCT06123026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 encapsulated placebo tablet given to participants after procedure
Study: NCT06429982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group
Study: NCT06617039
Drug: Remifentanil and ciprofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.
Study: NCT06192641
Drug: Melatonin 3 MG
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).
Study: NCT04819854
Drug: EP395
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule for oral treatment
Study: NCT04819854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule for oral treatment
Study: NCT06467201
Drug: KSHN001126 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive single oral dose of 150mg
Study: NCT06467201
Drug: KSHN001126 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive single oral dose of 300mg
Study: NCT06467201
Drug: KSHN001126 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects will receive single oral dose of 600mg
Study: NCT05397795
Drug: 10000 IU hCG (Choriomon5000 IU; IBSA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly
Study: NCT06587295
Drug: Intramuscular ACM-CpG Monotherapy (Escalation)
Normalized name: Acmella oleracea flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation for ACM-CpG monotherapy administered via intramuscular injection will similarly be conducted using traditional 3+3 dose escalation. Three dose levels have been planned. If the patient experiences a DLT or two Grade ≥ 2 drug-related toxicity, the dose level will be expanded according to a 3+3 design. The safety and tolerability of each dose level will be assessed by the study team after all patients enrolled in the dose level have been followed for at least 21 days after the first dose of the ACM-CpG (DLT observation period). Once the MTD is reached, the RP2D will be determined.
Study: NCT06587295
Drug: Intramuscular ACM-CpG Monotherapy (Expansion)
Normalized name: Acmella oleracea flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered ACM-CpG monotherapy at a dose determined in the dose escalation phase.
Study: NCT06594523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Tablet
Study: NCT06590454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14 days
Study: NCT05021484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion in regular intervals over 6 months
Study: NCT04291508
Drug: Intravenous Acetaminophen (room temperature)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs \< 50 kg) every six hours for 5 days (20 doses)
Study: NCT04012073
Drug: Neuromuscular Blocking Agents
Normalized name: NEUROMUSCULAR BLOCKING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive NMBA for 48 hours after the enrolment. The decision to stop NMBA administration after 48 hours will be left to the attending physician, but muscle paralysis will be strongly encouraged if PaO2/FiO2 ratio remains lower than 80-100 mmHg. NMBA administration will be resumed anytime deemed necessary by the attending physician.
Study: NCT06025552
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
Study: NCT04323462
Drug: Diabetic DM
Normalized name: Diabetic DM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously receiving OADs and/or basal insulin
Study: NCT06295094
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.1 mg/m2 body surface in 50ml saline
Study: NCT05985694
Drug: AD17002
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational intranasal pharmaceutical product named AD17002 contains a detoxified Escherichia coli heat-labile enterotoxin, LTh(αK).~Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.